YKYY-015

N/A

Report date: 2025/10/24 14:49:15
NME

Base Information

Drug NameYKYY-015
Drug Alias NameYKYY015YKYY-015
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaHyperlipidemiasHyperlipidemia, Familial Combined
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHangzhou Tianlong Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Tianlong Pharmaceutical Co LtdYoucare Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaHyperlipidemiasHyperlipidemia, Familial Combined
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A